The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin(482 views) D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, Fusco A
European Journal Of Cancer (ISSN: 0959-8049), 2013 Mar; 49(5): 1142-1151.
Keywords: Cancer, Chromatin, Hmga, Trabectedin, Cisplatin, High Mobility Group A Protein, Transcription Factor, Antineoplastic Activity, Article, Cancer Prognosis, Carcinoma Cell, Cell Transformation, Chromatin Structure, Colon Carcinoma, Controlled Study, Cytotoxicity, Female, Gene Repression, Genetic Transcription, Human, Human Cell, Human Tissue, Malignant Neoplastic Disease, Mouse, Nonhuman, Priority Journal, Promoter Region, Protein Expression, Protein Function, Thyroid Carcinoma, Antineoplastic Agents, Alkylating, Cultured, Dioxoles, Gene Expression Regulation, Hek293 Cells, Hmga Proteins, Protein Binding, Radiation Tolerance, Radiation-Sensitizing Agents, Signal Transduction, Tetrahydroisoquinolines, Transcriptional Activation, Validation Studies As Topic,
Affiliations: *** IBB - CNR ***
Istituto di Endocrinologia Ed Oncologia Sperimentale Del CNR, C/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università Degli Studi di Napoli Federico II, via Pansini 5, 80131 Napoli, Italy
Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy
Istituto di Biostrutture e Bioimmagini Del CNR, Naples, Italy
NOGEC (Naples Oncogenomic Center), CEINGE-Biotecnologie Avanzate, Napoli, SEMM-European School of Molecular Medicine-Naples Site, Naples, Italy
References: Not available.
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin
Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo. It interacts with the minor groove of DNA, interfering with transcriptional activity and DNA repair pathways. Here, we report a novel mechanism by which trabectedin exerts its cytotoxic effects on carcinoma cells. It is based on its ability to impair the function of the High-Mobility Group A (HMGA) proteins. These proteins have a key role in cell transformation, and their overexpression is a common feature of human malignant neoplasias, representing a poor prognostic index often correlated to anti-cancer drug resistance. They bind the minor groove of DNA, alter chromatin structure and, thus, regulate the transcription of several genes by enhancing or suppressing the activity of transcription factors. We first report that trabectedin has a higher cytotoxic effect on thyroid and colon carcinoma cells expressing abundant levels of HMGAs in comparison with cells not expressing them. Then, we have shown that trabectedin treatment displaces HMGA proteins from the HMGA-responsive promoters, including ATM promoter, impairing their transcriptional activity. Finally, we report a synergism between Ionising Radiations and trabectedin treatment restricted to the HMGA-overexpressing cancer cells. This result might have important clinical implications since it would suggest the use of trabectedin for the treatment of neoplasias expressing abundant HMGA levels that are frequently associated to chemoresistance and poor prognosis. (C) 2012 Elsevier Ltd. All rights reserved.
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(433 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(667 views) N Engl J Med (ISSN: 0028-4793, 0028-4793linking, 1533-4406electronic), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 ViewExport to BibTeXExport to EndNote